التفاصيل البيبلوغرافية
| العنوان: |
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. |
| المؤلفون: |
Keeping, Sam, Xu, Yingxin, Chen, Chieh-I, Cope, Shannon, Mojebi, Ali, Kuznik, Andreas, Konidaris, Gerasimos, Ayers, Dieter, Sasane, Medha, Allen, Rachel, Huynh, Thi-Minh-Thao, Popoff, Evan, Freeman, Morganna, Andria, Michael L, Fury, Matthew G, Singh, Kanwarjit, Stockfleth, Eggert, Challapalli, Amarnath, Schmults, Chrysalyne D |
| المصدر: |
Future Oncology; Feb2021, Vol. 17 Issue 5, p611-627, 17p |
| مستخلص: |
Aim: To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival. Patients & methods: We performed an indirect treatment comparison of cemiplimab and other available systemic therapies for patients with advanced cutaneous squamous cell carcinoma. Results: Cemiplimab was associated with benefits in OS (hazard ratios range: 0.07-0.52) and progression-free survival (hazard ratios range: 0.30-0.67) versus EGFR inhibitors and pembrolizumab (data from KEYNOTE-629). Cemiplimab was more efficacious versus platinum-based chemotherapy in terms of OS. Conclusion: Cemiplimab may offer improvements in survival for advanced cutaneous squamous cell carcinoma patients compared with existing systemic therapies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
